AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 8354918 — intervention group
Group type: EXPERIMENTAL
Intervention: ranitidine plus amoxicillin plus metronidazole
Number of subjects: 104
Study 8354918 — intervention group
Group type: COMPARATOR
Intervention: ranitidine plus placebo
Number of subjects: 104
Study 3490195 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol, 2.5 mg/kg IV for induction; 7 +/- 2 mg/min continuous infusion for maintenance
Number of subjects: 60
Study 3490195 — intervention group
Group type: COMPARATOR
Intervention: Methohexital, 1.5 mg/kg IV for induction; 6 +/- 2 mg/min continuous infusion for maintenance
Number of subjects: 60
Study 30889524 — intervention group
Group type: EXPERIMENTAL
Intervention: Pictorial HWLs
Number of subjects: 992
Study 30889524 — intervention group
Group type: EXPERIMENTAL
Intervention: 50% HWLs
Number of subjects: 992
Study 30889524 — intervention group
Group type: COMPARATOR
Intervention: No-HWL Control
Number of subjects: 992
Study 30889524 — intervention group
Group type: EXPERIMENTAL
Intervention: 30% HWLs
Number of subjects: 992
Study 28906205 — intervention group
Group type: EXPERIMENTAL
Intervention: Isosorbide mononitrate
Number of subjects: 60
Study 28906205 — intervention group
Group type: EXPERIMENTAL
Intervention: Cilostazol
Number of subjects: 60
Study 28906205 — intervention group
Group type: EXPERIMENTAL
Intervention: Isosorbide mononitrate and cilostazol (combined)
Number of subjects: 60
Study 27197106 — intervention group
Group type: EXPERIMENTAL
Intervention: Electromyographic biofeedback treatment after progressive muscular relaxation training
Number of subjects: 12
Study 27197106 — intervention group
Group type: COMPARATOR
Intervention: Waiting list control group
Number of subjects: 12
Study 24569437 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen
Number of subjects: 13388
Study 24569437 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13388
Study 24569437 — intervention group
Group type: EXPERIMENTAL
Intervention: Cigarette smoking (15-35 years)
Number of subjects: 13388
Study 24569437 — intervention group
Group type: EXPERIMENTAL
Intervention: Cigarette smoking (≥ 35 years)
Number of subjects: 13388
Study 24569437 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate alcohol consumption (>0-1 drink/day)
Number of subjects: 13388
Study 24569437 — intervention group
Group type: COMPARATOR
Intervention: Low physical activity
Number of subjects: 13388
Study 22854660 — intervention group
Group type: EXPERIMENTAL
Intervention: Quinvaxem (®) vaccine
Number of subjects: 360
Study 22854660 — intervention group
Group type: EXPERIMENTAL
Intervention: Booster dose of Quinvaxem (®)
Number of subjects: 360
Study 22854660 — intervention group
Group type: EXPERIMENTAL
Intervention: Quinvaxem (®) with concomitant measles vaccine
Number of subjects: 360
Study 22854660 — intervention group
Group type: EXPERIMENTAL
Intervention: Quinvaxem (®)
Number of subjects: 360
Study 22854660 — intervention group
Group type: EXPERIMENTAL
Intervention: Three production lots of Quinvaxem (®)
Number of subjects: 360
Study 20488469 — intervention group
Group type: COMPARATOR
Intervention: Low dose antibiotic prophylaxis
Number of subjects: 203
Study 20488469 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic therapy (dextranomer/hyaluronic acid copolymer)
Number of subjects: 203
Study 20488469 — intervention group
Group type: COMPARATOR
Intervention: Surveillance group on antibiotic treatment only for febrile urinary tract infection
Number of subjects: 203
Study 18564730 — intervention group
Group type: EXPERIMENTAL
Intervention: Bovine-derived hydroxyapatite combined with Cissus quadrangularis (CQ)
Number of subjects: 20
Study 18564730 — intervention group
Group type: COMPARATOR
Intervention: Bovine-derived hydroxyapatite alone
Number of subjects: 20
Study 16048456 — intervention group
Group type: EXPERIMENTAL
Intervention: AQ‐J (Autism Spectrum Quotient - Japanese version)
Number of subjects: 240
Study 16048456 — intervention group
Group type: EXPERIMENTAL
Intervention: AQ‐J-21 (21 items associated with HPDD diagnosis)
Number of subjects: 240
Study 16048456 — intervention group
Group type: EXPERIMENTAL
Intervention: AQ‐J-10 (10 items with effect size > 0.17)
Number of subjects: 240
Study 16048456 — intervention group
Group type: COMPARATOR
Intervention: AQ‐J
Number of subjects: 240
Study 12436050 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram
Number of subjects: 12
Study 12436050 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 12
Study 11227394 — intervention group
Group type: EXPERIMENTAL
Intervention: eletriptan 40 mg
Number of subjects: 692
Study 11227394 — intervention group
Group type: EXPERIMENTAL
Intervention: eletriptan 80 mg
Number of subjects: 692
Study 11227394 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 692
Study 9179553 — intervention group
Group type: COMPARATOR
Intervention: Yoga (6 weeks)
Number of subjects: 26
Study 9179553 — intervention group
Group type: COMPARATOR
Intervention: Aerobic training (6 weeks)
Number of subjects: 26
Study 8097280 — intervention group
Group type: EXPERIMENTAL
Intervention: EMD 49980 monotherapy
Number of subjects: 0
Study 8097280 — intervention group
Group type: EXPERIMENTAL
Intervention: EMD 49980 co-administered with levodopa
Number of subjects: 0
Study 2950359 — intervention group
Group type: EXPERIMENTAL
Intervention: VAC/FMC chemotherapy with bromoergocryptine
Number of subjects: 86
Study 2950359 — intervention group
Group type: COMPARATOR
Intervention: VAC/FMC chemotherapy without bromoergocryptine
Number of subjects: 86
Study 2950359 — intervention group
Group type: EXPERIMENTAL
Intervention: VAC/FMC chemotherapy with medroxyprogesterone acetate (MAP)
Number of subjects: 86
Study 2950359 — intervention group
Group type: COMPARATOR
Intervention: VAC/FMC chemotherapy without MAP
Number of subjects: 86
Study 31314693 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeted Temperature Management (TTM)
Number of subjects: 262
Study 31314693 — intervention group
Group type: COMPARATOR
Intervention: Standard Supportive Care (SSC)
Number of subjects: 262
Study 31486272 — intervention group
Group type: EXPERIMENTAL
Intervention: SGLT2 inhibitors
Number of subjects: 0
Study 31486272 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 27393139 — intervention group
Group type: EXPERIMENTAL
Intervention: Lithium carbonate 25 mg/kg TBW/day in two daily doses
Number of subjects: 61
Study 27393139 — intervention group
Group type: EXPERIMENTAL
Intervention: Lithium carbonate
Number of subjects: 61
Study 25965624 — intervention group
Group type: EXPERIMENTAL
Intervention: Creatinine
Number of subjects: 190
Study 25965624 — intervention group
Group type: EXPERIMENTAL
Intervention: NGAL
Number of subjects: 190
Study 25965624 — intervention group
Group type: EXPERIMENTAL
Intervention: KIM-1
Number of subjects: 190
Study 25965624 — intervention group
Group type: EXPERIMENTAL
Intervention: CysC
Number of subjects: 190
Study 23117500 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV testing and counseling (timing of first testing: 0-7 days)
Number of subjects: 508
Study 23117500 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV testing and counseling (timing of first testing: 8-14 days)
Number of subjects: 508
Study 23117500 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV testing and counseling (timing of first testing: 15-30 days)
Number of subjects: 508
Study 23117500 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV testing and counseling (timing of first testing: >30 days)
Number of subjects: 508
Study 21639864 — intervention group
Group type: EXPERIMENTAL
Intervention: Age‐related, height‐based (ARHB)
Number of subjects: 173
Study 21639864 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct distance nose‐ear‐mid‐umbilicus (NEMU)
Number of subjects: 173
Study 21639864 — intervention group
Group type: COMPARATOR
Intervention: Direct distance nose‐ear‐xiphoid (NEX)
Number of subjects: 173
Study 19931755 — intervention group
Group type: EXPERIMENTAL
Intervention: MAR Method (using a fist to cover a surface area of blood)
Number of subjects: 74
Study 16766279 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg hydrochlorothiazide (HCT)
Number of subjects: 28
Study 16766279 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg hydrochlorothiazide (HCT) and 5 mg amyloride
Number of subjects: 28
Study 16766279 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg hydrochlorothiazide (HCT) and 50 mg spironolactone
Number of subjects: 28
Study 16766279 — intervention group
Group type: COMPARATOR
Intervention: HCT-spironolactone vs HCT and HCT-amyloride
Number of subjects: 28
Study 15233245 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised outpatient exercise training program (3 times weekly on non-dialysis days)
Number of subjects: 48
Study 15233245 — intervention group
Group type: COMPARATOR
Intervention: Training program with stationary bicycles during HD sessions (3 times weekly)
Number of subjects: 48
Study 15233245 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 48
Study 15233245 — intervention group
Group type: EXPERIMENTAL
Intervention: Group A
Number of subjects: 48
Study 11079993 — intervention group
Group type: EXPERIMENTAL
Intervention: Health information with a medical award present on the page
Number of subjects: 137
Study 11079993 — intervention group
Group type: COMPARATOR
Intervention: Health information without a medical award present on the page
Number of subjects: 137
Study 9134070 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine patch plus four smoking cessation sessions with a nurse-practitioner (moderate-intensity condition, MI)
Number of subjects: 69
Study 9134070 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine patch plus four smoking cessation sessions plus 16 weekly individual cognitive/behavioral relapse-prevention therapy sessions (high-intensity condition, HI)
Number of subjects: 69
Study 7955243 — intervention group
Group type: EXPERIMENTAL
Intervention: Right gastroepiploic artery (GEA)
Number of subjects: 290
Study 7955243 — intervention group
Group type: EXPERIMENTAL
Intervention: Inferior epigastric artery (IEA)
Number of subjects: 290
Study 3310727 — intervention group
Group type: EXPERIMENTAL
Intervention: Nalbuphine (NAL) 1.5 mg/kg BW
Number of subjects: 20
Study 3310727 — intervention group
Group type: EXPERIMENTAL
Intervention: Nalbuphine (NAL) 2.5 mg/kg BW
Number of subjects: 20
Study 3310727 — intervention group
Group type: COMPARATOR
Intervention: Fentanyl (FE) 0.005 mg/kg BW
Number of subjects: 20
Study 29344405 — intervention group
Group type: EXPERIMENTAL
Intervention: LSVT LOUD® (16 sessions over 4 weeks)
Number of subjects: 89
Study 29344405 — intervention group
Group type: EXPERIMENTAL
Intervention: SLT (individualised content, typically weekly sessions for 6-8 weeks)
Number of subjects: 89
Study 29344405 — intervention group
Group type: COMPARATOR
Intervention: Control (no intervention)
Number of subjects: 89
Study 28253897 — intervention group
Group type: COMPARATOR
Intervention: Complex intervention delivered over 12 months to promote recruitment.
Number of subjects: 72
Study 26582115 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational video program
Number of subjects: 101
Study 26582115 — intervention group
Group type: COMPARATOR
Intervention: Verbal education with explanatory note (Control)
Number of subjects: 101
Study 23254770 — intervention group
Group type: EXPERIMENTAL
Intervention: Losmapimod
Number of subjects: 77
Study 21681652 — intervention group
Group type: EXPERIMENTAL
Intervention: MOXI‐AF (0.5% moxifloxacin ophthalmic solution) dosed twice-daily for 3 days
Number of subjects: 1180
Study 21681652 — intervention group
Group type: COMPARATOR
Intervention: Vehicle control
Number of subjects: 1180